Articles and Videos
Loading...
December 1, 2021
InMed Welcomes the BayMedica Team! Meet Philip Barr, VP of Discovery Research
InMed Pharmaceuticals is pleased to welcome to the BayMedica team following its acquisition in October 2021. Meet Philip Barr, our VP of Discovery Research. Phil...
Source:
Edison TV
November 30, 2021
InMed’s Pharmaceutical Programs in Epidermolysis Bullosa and Glaucoma and Pharma Partnership Opportunities
In this excerpt from The Dales Report interview with host Shadd Dales, InMed's CEO Eric A. Adams talks about the Company's pharmaceutical programs in Epidermolysis...
Source:
The Dales Report
November 23, 2021
InMed welcomes the BayMedica team! Meet Shane Johnson, SVP and General Manager
InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Shane Johnson, our Senior Vice President and General Manager....
Source:
Edison TV
November 16, 2021
InMed welcomes the BayMedica team! Meet Chris Meiering, VP of Commercial Operations
InMed Pharmaceuticals is pleased to welcome the BayMedica team following the acquisition in October 2021. Meet Chris Meiering, our VP of Commercial Operations. Chris talks...
Source:
Edison TV
November 8, 2021
The Dales Report Interview: InMed Pharmaceuticals Makes Noise With Patent Application & Acquisition: Cannabis Stock Investing
Shadd Dales of The Dales Report asks InMed CEO, Eric A. Adams, about the recent news of InMed’s patent application for a cannabinoid treatment targeting...
Source:
The Dales Report
November 8, 2021
InMed’s early studies of CBN show the potential to reduce intraocular pressure and provide neuroprotection.
In this interview with The Dales Report, InMed CEO Eric A. Adams talks about the company’s glaucoma program and the early studies are showing how...
Source:
The Dales Report